Company advances Phase 3 AXPAXLI programs, with SOL-1 Week 52 data presentation set for February 2026 and SOL-R topline expected in Q1 2027.

RIT researchers solve multiple tissue engineering challenges by developing a novel hydrogel to host human cells and a device to 3D print bioinks safely.

Ocular Therapeutix reported a phase 3 win that it believes can validate its attempts to challenge Regeneron’s entrenched ...

AXPAXLI (TM) (also known as OTX-TKI) is an investigational, bioresorbable, intravitreal hydrogel incorporating axitinib, a small molecule, multi-target, tyrosine kinase inhibitor with anti-angiogenic ...

A grape, sliced nearly in half and placed in a household microwave, can produce a bright flash of plasma, the same high-energy state of matter found in lightning bolts and the surface of the sun. For ...

Phase 1 maximal-use pharmacokinetics (PK) study completed in support of planned U.S. label expansion Data to complement ...

Following the successful late-stage study in wet age-related macular degeneration, Ocular plans to meet with the FDA to ...

First ever successful demonstration of superiority in an FDA-aligned wet AMD trial comparing a novel investigative agent to ...

In pain relief and physical rehabilitation, TENS-based therapies are widely used to support non-pharmacological treatment strategies. Reusable electrode pads enable patients to conduct multiple ...

DOVER, DE, UNITED STATES, January 21, 2026 /EINPresswire.com/ -- The global pharmaceutical supply chain is currently ...

This octopus-inspired smart skin can change shape and reveal hidden secrets on command.

A bill aimed at shielding Oklahoma residential energy customers from potential rate hikes tied to large power users has ...